Figure 5.
Efficacy of NDV in a Setting of Recurrent Tumor in the Presence of Anti-NDV Immunity
(A) Treatment scheme. Primary tumors were established by implantation of 1 × 105 B16-F10 cells in the right flank. Recurrent tumors were modeled by implantation of 4 × 105 B16-F10 cells in the left flank. (B) Individual tumor growth. (C) Overall survival. Data represent one of two independent experiments with n = 5 (B16-naive PBS), n = 4 (B16 re-implanted PBS), n = 5 (B16 naive NDV), and n = 9 (B16 re-implanted NDV) mice per group. ***p < 0.001.